Skip to main content

Table 1 A summary of baseline patient characteristics

From: Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention

   Intensive (n = 132) Standard (n = 130) Observational (n = 61) Difference between groups
Ethnicity (%) White 116 (87.9) 107 (82.3) 58 (95.1)  
Afro-Caribbean 5 (3.8) 11 (8.5) 0
South Asian 9 (6.8) 9 (6.9) 1 (1.6)
Other 2 (1.5) 3 (2.3) 2 (3.3)
Form of diabetes (%) Type 1 diabetes 69 (52.3) 65 (50) 24 (39.3) p = 0.24
Type 2 diabetes 60 (45.4) 64 (49.2) 36 (59) p = 0.22
Other diabetes 3 (2.3) 1 (0.8) 1 (1.6) NA
Male gender (%) Total 83 (62) 76 (58.5) 35 (57.4) p = 0.68
T1D 48 (69.6) 38 (58.5) 16 (66.7) p = 0.40
T2D 33 (55) 37 (57.8) 18 (50) p = 0.75
Age (years ± SD) Total 61.4 ± 1 8.5 62.0 ± 18.7 70.3 ± 14.0 p = 0.03
T1D 50.5 ± 16.7 49.7 ± 16.5 59.7 ± 12.9 p = 0.03
T2D 74.2 ± 10.7 74.84 ± 10.2 77.3 ± 9.8 p = 0.38
Presenting capillary glucose (mmol/L ± SD) Total 2.1 ± 0.7 2.2 ± 1.0 2.1 ± 0.6 p = 0.79
T1D 2.0 ± 0.7 2.1 ± 1.2 1.9 ± 0.6 p = 0.73
T2D 2.3 ± 0.7 2.3 ± 0.8 2.3 ± 0.6 p = 0.94
HbA1c (mmol/mol ± SD) Total 62.8 ± 17.1 63.5 ± 15.6 60.8 ± 17.0 p = 0.62
T1D 66.3 ± 19.4 66.8 ± 14.5 61.3 ± 10.5 p = 0.40
T2D 58.5 ± 13.4 60.0 ± 16.2 61.2 ± 20.4 p = 0.76
Current smoker (%) Total 29 (22.0) 27 (20.8) 10 (16.4) p = 0.66
T1D 22 (31.9) 18 (27.7) 5 (20.8) p = 0.45
T2D 7 (11.7) 9 (14.0) 5 (13.9) p = 0.91
Duration of diabetes (years ± SD) Total 23.7 ± 14.0 23.1 ± 12.7 25.7 ± 13.7 p = 0.58
T1D 26.3 ± 15.6 27.2 ± 13.1 32.0 ± 12.0 p = 0.25
T2D 21.0 ± 11.3 19.3 ± 10.7 20.9 ± 3.3 p = 0.67
BMI (kg/m2 ± SD) Total 28.6 ± 7.4 27. 9 ± 6.8 27.1 ± 5.6 p = 0.43
T1D 26.9 ± 7.4 26.6 ± 7.4 25.6 ± 3.4 p = 0.75
T2D 31.0 ± 7.7 29.5 ± 5.8 28.1 ± 6.7 p = 0.18
Established cardiovascular disease (%) Total 35 (26.5) 43 (33.1) 26 (42.6) p = 0.08
T1D 13 (18.8) 13 (20) 8 (33.3) p = 0.31
T2D 21 (35) 30 (46.9) 18 (50) p = 0.26
Antiplatelet use (%) Total 48 (36.4) 49 (37.7) 28 (45.9) p = 0.43
T1D 17 (24.6) 20 (30.1) 9 (37.5) p = 0.46
T2D 88 (66.7) 29 (45.3) 19 (52.8) p = 0.75
Lipid lowering therapy use (%) Total 30 (50) 84 (64.6) 42 (68.9) p = 0.84
T1D 36 (52.2) 37 (56.9) 17 (70.8) p = 0.28
T2D 50 (83.3) 47 (73.4) 24 (66.7) p = 0.16
Anti-hypertensive use (%) Total 81 (61.4) 83 (63.8) 41 (67.2) p = 0.73
T1D 30 (43.4) 30 (46.2) 17 (70.8) p = 0.06
T2D 50 (83.3) 53 (82.8) 23 (63.9) p = 0.05
Type 2 diabetes receiving insulin (%)   48 (80) 53 (82.8) 26 (72.2) p = 0.45
  1. Data are presented as number (%) or mean ± SD
  2. Numbers in italics signify statistically significant differences